Stock Research for IPCI

IPCI

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

IPCI Stock Chart & Research Data

The IPCI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IPCI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


IPCI Due diligence Resources & Stock Charts

The IPCI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View IPCI Detailed Price Forecast - CNN Money CNN View IPCI Detailed Summary - Google Finance
Yahoo View IPCI Detailed Summary - Yahoo! Finance Zacks View IPCI Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View IPCI Trends & Analysis - Trade-Ideas Barrons View IPCI Major Holders - Barrons
NASDAQ View IPCI Call Transcripts - NASDAQ Seeking View IPCI Breaking News & Analysis - Seeking Alpha
Spotlight View IPCI Annual Report - CompanySpotlight.com OTC Report View IPCI OTC Short Report - OTCShortReport.com
TradeKing View IPCI Fundamentals - TradeKing Charts View IPCI SEC Filings - Bar Chart
WSJ View Historical Prices for IPCI - The WSJ Morningstar View Performance/Total Return for IPCI - Morningstar
MarketWatch View the Analyst Estimates for IPCI - MarketWatch CNBC View the Earnings History for IPCI - CNBC
StockMarketWatch View the IPCI Earnings - StockMarketWatch MacroAxis View IPCI Buy or Sell Recommendations - MacroAxis
Bullish View the IPCI Bullish Patterns - American Bulls Short Pains View IPCI Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View IPCI Stock Mentions - StockTwits PennyStocks View IPCI Stock Mentions - PennyStockTweets
Twitter View IPCI Stock Mentions - Twitter Invest Hub View IPCI Investment Forum News - Investor Hub
Yahoo View IPCI Stock Mentions - Yahoo! Message Board Seeking Alpha View IPCI Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for IPCI - SECform4.com Insider Cow View Insider Transactions for IPCI - Insider Cow
CNBC View IPCI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for IPCI - OTC Markets
Yahoo View Insider Transactions for IPCI - Yahoo! Finance NASDAQ View Institutional Holdings for IPCI - NASDAQ


Stock Charts

FinViz View IPCI Stock Insight & Charts - FinViz.com StockCharts View IPCI Investment Charts - StockCharts.com
BarChart View IPCI Stock Overview & Charts - BarChart Trading View View IPCI User Generated Charts - Trading View




Latest Financial News for IPCI


Intellipharmaceutics Announces FDA Tentative Approval of Generic Pristiq(R)
Posted on Wednesday February 20, 2019

TORONTO, ON / ACCESSWIRE / February 20, 2019 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the Company's abbreviated new drug application ("ANDA") for desvenlafaxine extended-release tablets in the 50 and 100 mg strengths. The approved product is a generic equivalent of the branded product Pristiq® sold in the U.S. by Wyeth Pharmaceuticals, LLC ("Wyeth"). The Company previously announced that it had entered into a license and commercial supply agreement with Mallinckrodt LLC ("Mallinckrodt"), which granted Mallinckrodt, subject to its terms, an exclusive license to market, sell and distribute in the U.S. the Company's desvenlafaxine extended-release tablets (generic Pristiq®).


Intellipharmaceutics Receives Extension from Nasdaq Hearings Panel
Posted on Monday January 28, 2019

TORONTO, ONTARIO / ACCESSWIRE / January 28, 2019 / Intellipharmaceutics International Inc. (NASDAQ: IPCI) and (TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received notice from the Nasdaq Hearings Panel (the ''Panel'') extending the continued listing of the Company's common shares until March 7, 2019, subject to certain conditions, while the Company works to regain compliance with Nasdaq's requirements. At a hearing held on January 10, 2019, the Company presented its plan to regain and maintain compliance with Nasdaq's continued listing requirements.


Intellipharmaceutics Announces Research and Development Program for a Pipeline of Pharmaceutical Cannabidiol Based Products
Posted on Monday January 07, 2019

TORONTO, ON / ACCESSWIRE / January 7, 2019 / Intellipharmaceutics International Inc. (NASDAQ: IPCI) and (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has commenced a research and development program of pharmaceutical cannabidiol ("CBD") based products. The Company believes that its current technology platforms could find use in cannabidiol therapeutics.


NASDAQ Schedules Hearing to Consider Intellipharmaceutics’ (TM) Continued Listing
Posted on Tuesday December 04, 2018

TORONTO, ON / ACCESSWIRE / December 5, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received written notification (the ''Notification'')from The Nasdaq Stock Market LLC ('NASDAQ'') notifying the Company that a hearing with a Nasdaq Hearings Panel (the ''Panel'')has been scheduled for January 10, 2019. As previously reported, the minimum bid price per share for the Company's common shares was below $1.00 for a period of 30 consecutive business days and, as a result, the Company is currently not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).


Stock Market & Investing Books

Enter a stock symbol to view the stock details.